(155 days)
The URiSCAN S-300 Semi-Automated Urine Chemistry Analyzer is a urine analyzer for detection of Occult Blood, Bilirubin, Urobilinogen, Ketones, Protein, Nitrite, Glucose, pH, Specific Gravity, Leukocytes and Ascorbic Acid in urine specimens through the reflectance method.
The URISCAN S-300 Semi-Automated Urine Chemistry Analyzer is a line operated unit which translates color and intensity of light reflected from reacted reagent pads into clinical units and displays the results. The instrument is specifically designed to "read" YEONGDONG URiSCAN urinalysis reagent strips (See K952307). The URiSCAN S-300 Semi-Automated Urine Chemistry system includes tests for the following physical properties and chemical constituents of urine: specific gravity, pH, Blood, Bilirubin, Urobilinogen, Ketones, Protein, Nitrite, Glucose, Leukocytes and Ascorbic Acid. The instrument uses a light source produced by cold fluorescent lamp.
The provided document describes the URiSCAN S-300 Semi-Automated Urine Chemistry Analyzer and its substantial equivalence to predicate devices, but it does not contain specific acceptance criteria with numerical targets or detailed results from a study demonstrating the device meets such criteria. The information is high-level and focuses on the equivalence to existing devices rather than a detailed performance study against pre-defined acceptance metrics.
Below is an attempt to structure the information based on the request, acknowledging the limitations of the provided text.
Description of Acceptance Criteria and Study to Prove Device Meets Acceptance Criteria
The provided 510(k) summary for the URiSCAN S-300 Semi-Automated Urine Chemistry Analyzer describes its analytical performance evaluation to demonstrate substantial equivalence to legally marketed predicate devices. However, it does not explicitly state pre-defined numerical "acceptance criteria" for precision, accuracy, or linearity. Instead, the study's goal appears to be demonstrating "similar" performance to the predicates.
1. Table of Acceptance Criteria and Reported Device Performance
As explicit numerical acceptance criteria are not provided in the document, this table will reflect the general nature of the reported performance (similarity to predicate devices) for the evaluated metrics.
| Performance Metric | Acceptance Criteria (Not Explicitly Stated as Numerical Targets) | Reported Device Performance |
|---|---|---|
| Precision | Performance should be similar to predicate devices | Evaluated for precision, described as performing "similarly to the predicate devices." |
| Accuracy | Performance should be similar to predicate devices | Evaluated for accuracy, described as performing "similarly to the predicate devices." |
| Linearity | Performance should be similar to predicate devices | Evaluated for linearity, described as performing "similarly to the predicate devices." |
| Correlation | Performance should be comparable to predicate devices | Evaluated for correlation with the Ames/Miles, Inc. (Bayer) Clinitek 200 Semi-automated Urinalysis System and the Boehringer Mannheim Chemstrip Super UA Urine Analyzer predicate devices. Found to perform "similarly to the predicate devices." Comparative clinical evaluations were also conducted using a Clinitek 200+ system as a reference analyzer. |
2. Sample Size Used for the Test Set and Data Provenance
The document does not explicitly state the sample size used for the clinical tests on patient urine specimens. It mentions tests were conducted on "patient urine specimens" and "at two different laboratories."
- Sample Size for Test Set: Not explicitly stated.
- Data Provenance: "Patient urine specimens." The document does not specify the country of origin of the data, but the submitter is from Seoul, Korea, and the 510(k) summary was prepared in the US, so it's possible the data could be from either or both regions. The study appears to be prospective in nature, as it describes "clinical tests performed" and "comparative clinical evaluations."
3. Number of Experts Used to Establish Ground Truth for the Test Set and Their Qualifications
The document does not mention the use of human experts to establish ground truth. The comparison is made against existing predicate automated urinalysis systems (Ames/Miles, Inc. (Bayer) Clinitek 200 Semi-automated Urinalysis System, Boehringer Mannheim Chemstrip Super UA Urine Analyzer, and Clinitek 200+ system). Therefore, the "ground truth" for the test set appears to be derived from these established, legally marketed devices.
4. Adjudication Method for the Test Set
No adjudication method involving human experts is described, as the comparison is against predicate devices.
5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study
No MRMC study is mentioned. The device is a "Semi-Automated Urine Chemistry Analyzer," implying it performs the analysis rather than assisting human readers directly in interpreting images or data. Therefore, an MRMC study comparing human readers with and without AI assistance is not applicable to this type of device.
6. Standalone Performance Study (Algorithm Only Without Human-in-the-Loop Performance)
Yes, a standalone performance study was conducted. The "analytical performance of the URiSCAN S-300 Semi-Automated Urine Chemistry Analyzer on patient urine specimens was evaluated for precision, accuracy, linearity and correlation." This refers to the device's performance as a standalone automated system.
7. Type of Ground Truth Used
The ground truth for the performance evaluation was established by comparison to legally marketed predicate devices, specifically:
- Ames/Miles, Inc. (Bayer) Clinitek 200 Semi-automated Urinalysis System (K842237)
- Boehringer Mannheim Chemstrip Super UA Urine Analyzer (K934042)
- Clinitek 200+ system (used as a reference analyzer in comparative clinical evaluations)
These predicate devices serve as the "true" or reference measurements against which the URiSCAN S-300's results were compared.
8. Sample Size for the Training Set
The document does not mention a "training set" or a sample size for one. This device is a semi-automated chemical analyzer, not a machine learning or AI-based diagnostic tool that typically requires a separate training set. Its technology relies on reflectance spectrophotometry rather than pattern recognition or AI algorithms learned from data.
9. How the Ground Truth for the Training Set Was Established
Not applicable, as no training set for an AI/ML algorithm is described.
{0}------------------------------------------------
JUN 10 1998
mdi
EXHIBIT #1 510(k) SUMMARY
510(k) SUMMARY
Submitter's Information: 1.
Sanders Chung YEONGONG Pharmaceutical Corporation 288-14, Sindang-Dong, Jung-Gu 100-450 Seoul, Korea Tel: 213 267-1000 Fax: 213 263-1000
510(k) Summary Prepared by:
Thomas J. Bouchard mdi CONSULTANTS, INC. 55 Northern Blvd. Great Neck, NY 11021 Tel: (516) 482-9001
- December 17, 1997 Date 510(k) Summary Prepared: 2.
- Name of the Device: 3.
| Trade or Proprietary Name: | URiSCAN S-300 Semi-Automated UrineChemistry Analyzer |
|---|---|
| Common Name: | Semi-Automated Urinalysis System |
| Classification Name: | Automated Urinalysis System |
{1}------------------------------------------------
Identification of legally marketed devices which the submitter claims 4. equivalence.
The URiSCAN S-300 Semi-Automated Urine Chemistry Analyzer is substantially equivalent for purposes of Section 510(k) of the Federal Food, Drug and Cosmetic Act to the Ames/Miles, Inc. Clinitek 200 Semi-automated Urinalysis System (K842237), and the Boehringer Mannheim (Hitachi) Miditron Urine Analyzer system (K934042) in significant features, materials and intended use.
5. Description of the Subject Device:
The URISCAN S-300 Semi-Automated Urine Chemistry Analyzer is a line operated unit which translates color and intensity of light reflected from reacted reagent pads into clinical units and displays the results. The instrument is specifically designed to "read" YEONGDONG URiSCAN urinalysis reagent strips (See K952307). The URiSCAN S-300 Semi-Automated Urine Chemistry system includes tests for the following physical properties and chemical constituents of urine: specific gravity, pH, Blood, Bilirubin, Urobilinogen, Ketones, Protein, Nitrite, Glucose, Leukocytes and Ascorbic Acid.
The instrument uses a light source produced by cold fluorescent lamp.
6. Intended Use of the Subject Devices:
The URISCAN S-300 Semi-Automated Urine Chemistry Analyzer is a urine analyzer for detection of Occult Blood, Bilirubin, Urobilinogen, Ketones, Protein, Nitrite, Glucose, pH. Specific Gravity, Leukocytes and Ascorbic Acid in urine specimens through the reflectance method.
7. Technological Characteristics of the Subject Devices.
The URISCAN S-300 Semi-Automated Urine Analyzer and each of the above mentioned urine chemistry analyzers used in the comparison are all desk top models that operate using the reflectance principal, have an LCD display and provide quantitative and qualitative test results. The URiSCAN S-300 uses a color CCD (Charge Coupled Device) technology whereas the other units use photo diode technology. The color CCD technology provides an analysis capacity over the entire visible wavelength, while the other units analysis capacity is limited to only certain wavelengths.
{2}------------------------------------------------
8. Discussion of Clinical Tests Performed:
The analytical performance of the URiSCAN S-300 Semi-Automated Urine Chemistry Analyzer on patient urine specimens was evaluated for precision, accuracy, linearity and correlation with the Ames/Miles, Inc.(Bayer) Clinitek 200 Semi-automated Urinalysis System and the Boehringer Mannheim Chemstrip Super UA Urine Analyzer predicate devices. Comparative clinical evaluations were also conducted at two different laboratories using a Clinitek 200+ system as a reference analyzer. The clinical testing found the URiSCAN S-300 to perform similarly to the predicate devices.
9. Conclusions:
In summary, based on comparison with legally marketed devices and tests of this device to demonstrate compliance to EN 60601-1-2:1993, the subject URiSCAN S-300 is safe and effective and performs as well as the legally marketed predicate devices.
{3}------------------------------------------------
Image /page/3/Picture/1 description: The image is a black and white circular seal for the Department of Health & Human Services - USA. The seal features the department's name in a circular arrangement around the perimeter. In the center of the seal is a stylized image of a bird-like figure, possibly representing an eagle or other national symbol. The overall design is simple and professional, reflecting the department's role in public health and human services.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
JUN 10 1998
Yeongdong Pharmaceutical Corporation C/O MDI Consultants, Inc. Thomas J. Bouchard 55 Northern Boulevard Great Neck, New York 11021
Re : K980047 URiSCAN S-300 Semi-Automated Urine Chemistry Analyzer Requlatory Class: II Product Code: KQO, JIL, LJX April 14, 1998 Dated: Received: April 16, 1998
Dear Mr. Bouchard:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions The general controls provisions of the Act . of the Act. include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major requlations affecting your device can be found in the Code of Federal Requlations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical General regulation (21 CFR Part 820) and that, Devices: through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP requlation may result in regulatory In addition, FDA may publish further announcements action. concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
{4}------------------------------------------------
Page 2
Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770) 488-7655.
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions-on--the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html".
Sincerely yours,
Steven Gutman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{5}------------------------------------------------
Exhibit A
Page 1 of 1
510(k) Number (if known): _
Device Name: URiSCAN S-300 Semi-Automated Urine Chemistry Analyzer
Indications For Use:
Section 3 - Intended Use
The URiSCAN S-300 Semi-Automated Urine Chemistry Analyzer is a urine analyzer for detection of Occult Blood, Bilirubin, Urobilinogen, Ketones, Protein, Nitrite, Glucose, pH, Specific Gravity, Leukocytes and Ascorbi Acid in urine specimens through the reflectance method.
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
OR
(Division Sign-Off)
Division of Clinical Laboratory Devices
510(k) Number K980047
Prescription Use_ (Per 21 CFR 801.109)
Over-The-Counter Use_
(Optional Format 1-2-96)
§ 862.2900 Automated urinalysis system.
(a)
Identification. An automated urinalysis system is a device intended to measure certain of the physical properties and chemical constituents of urine by procedures that duplicate manual urinalysis systems. This device is used in conjunction with certain materials to measure a variety of urinary analytes.(b)
Classification. Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 862.9.